Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Efforts to understand barriers and to increase rates of molecular testing and ...

Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: a Meta-analysis of Randomized Controlled Trials This study confirms emerging data from a ...

The model suggests that negative KRAS findings are believable when the maximum of APC and TP53 frequencies is at least 8% (corresponding posterior probability of false negative <5%). Validation ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

Q: Should I be tested for the KRAS mutation before beginning colorectal cancer treatment? Recent research confirmed that the mutation status of the KRAS gene in colon cancer patients can determine if ...

Laboratory Corporation of America Holdings or LabCorp LH recently announced the availability of therascreen KRAS PCR Mutation Analysis -- a companion diagnostic (CDx) to spot patients with non-small ...

Please provide your email address to receive an email when new articles are posted on . Less than half of patients received MSI testing and about one-quarter received KRAS testing. Older age, rural ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments. Genetic testing is a laboratory method ...

QIAGEN N.V. announced that Clarient has adopted the use of the therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux® (cetuximab) as a treatment ...